Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers

Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical research 2007-07, Vol.24 (7), p.1336-1345
Hauptverfasser: MAHER, Sam, FEIGHERY, Linda, BRAYDEN, David J, MCCLEAN, Siobhan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1345
container_issue 7
container_start_page 1336
container_title Pharmaceutical research
container_volume 24
creator MAHER, Sam
FEIGHERY, Linda
BRAYDEN, David J
MCCLEAN, Siobhan
description Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2. The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors. Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling. Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins.
doi_str_mv 10.1007/s11095-007-9288-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20725578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20725578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</originalsourceid><addsrcrecordid>eNp1kU-LFDEQxYMo7uzqB_AiQVlvWVNJp5Pemyz-GVjxouAtpDOJm6U7mU16hPn21jgDC4KnFFW_evXII-QV8CvgXL9vAHxQDEs2CGOYeEJWoLRkA-9-PiUrrkXHjO7gjJy3ds85NzB0z8kZaKml0t2KPHwNU1qWlKlr1GUatmm5w5ab6DbUObgx4XxPQ75z2Yd6RdfXdJ1_h7akX25JJdMSaVoanYNHJLX50HD-7whlvfOFCTqXXCa3D7W9IM-im1p4eXovyI9PH7_ffGG33z6vbz7cMt8ZWJg2o-E9moxxiHrYSDmGTSf63geIzoAeAUS_0Xr0chBRG4cLIPWoRqW4CPKCvDvqbmt52KFfO6fmwzS5HMquWYG_o5Q2CL79B7wvu5rRm8VzCtW1AKTe_JcSyEmlJEJwhHwtrdUQ7bam2dW9BW4PkdljZPZQHiKzAnden4R34xw2jxunjBC4PAGueTfFikGk9sgZ0xvoBvkHbC6dZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222663553</pqid></control><display><type>article</type><title>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>MAHER, Sam ; FEIGHERY, Linda ; BRAYDEN, David J ; MCCLEAN, Siobhan</creator><creatorcontrib>MAHER, Sam ; FEIGHERY, Linda ; BRAYDEN, David J ; MCCLEAN, Siobhan</creatorcontrib><description>Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2. The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors. Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling. Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-007-9288-2</identifier><identifier>PMID: 17373574</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Actin ; Actins - metabolism ; Antimicrobial peptides ; Aristolochic acid ; Aristolochic Acids - pharmacology ; Biological and medical sciences ; Caco-2 Cells ; Cadherins - metabolism ; Cell Survival - drug effects ; Cellular biology ; Cyclooxygenase Inhibitors - pharmacology ; Cytotoxicity ; Dextrans - chemistry ; Dextrans - metabolism ; Dose-Response Relationship, Drug ; E-cadherin ; Electric Impedance ; Electrical resistivity ; Enzyme Inhibitors - pharmacology ; Fluorescein-5-isothiocyanate - analogs &amp; derivatives ; Fluorescein-5-isothiocyanate - chemistry ; Fluorescein-5-isothiocyanate - metabolism ; Fluorescent indicators ; Gene expression ; General pharmacology ; Humans ; Immunofluorescence ; Indomethacin ; Indomethacin - pharmacology ; Intestinal Absorption - drug effects ; Intestinal Mucosa - drug effects ; Intestinal Mucosa - metabolism ; Mannitol ; Medical sciences ; Melitten - pharmacology ; Membrane Proteins - metabolism ; Molecular Weight ; Peptides ; Permeability ; Permeability - drug effects ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology ; Pharmacology. Drug treatments ; Phospholipase A2 ; Phospholipases A - antagonists &amp; inhibitors ; Phospholipases A - metabolism ; Phospholipases A2 ; Phosphoproteins - metabolism ; Piroxicam ; Piroxicam - pharmacology ; Prostaglandin endoperoxide synthase ; Prostaglandin-Endoperoxide Synthases - metabolism ; Prostaglandins - metabolism ; Proteins ; Signal Transduction - drug effects ; Tight junctions ; Tight Junctions - drug effects ; Tight Junctions - metabolism ; Time Factors ; Western blotting ; Zonula Occludens-1 Protein</subject><ispartof>Pharmaceutical research, 2007-07, Vol.24 (7), p.1336-1345</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC 2007</rights><rights>Springer Science+Business Media, LLC 2007.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</citedby><cites>FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18868149$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17373574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAHER, Sam</creatorcontrib><creatorcontrib>FEIGHERY, Linda</creatorcontrib><creatorcontrib>BRAYDEN, David J</creatorcontrib><creatorcontrib>MCCLEAN, Siobhan</creatorcontrib><title>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><description>Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2. The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors. Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling. Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins.</description><subject>Actin</subject><subject>Actins - metabolism</subject><subject>Antimicrobial peptides</subject><subject>Aristolochic acid</subject><subject>Aristolochic Acids - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Caco-2 Cells</subject><subject>Cadherins - metabolism</subject><subject>Cell Survival - drug effects</subject><subject>Cellular biology</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Cytotoxicity</subject><subject>Dextrans - chemistry</subject><subject>Dextrans - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>E-cadherin</subject><subject>Electric Impedance</subject><subject>Electrical resistivity</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fluorescein-5-isothiocyanate - analogs &amp; derivatives</subject><subject>Fluorescein-5-isothiocyanate - chemistry</subject><subject>Fluorescein-5-isothiocyanate - metabolism</subject><subject>Fluorescent indicators</subject><subject>Gene expression</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Immunofluorescence</subject><subject>Indomethacin</subject><subject>Indomethacin - pharmacology</subject><subject>Intestinal Absorption - drug effects</subject><subject>Intestinal Mucosa - drug effects</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Mannitol</subject><subject>Medical sciences</subject><subject>Melitten - pharmacology</subject><subject>Membrane Proteins - metabolism</subject><subject>Molecular Weight</subject><subject>Peptides</subject><subject>Permeability</subject><subject>Permeability - drug effects</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phospholipase A2</subject><subject>Phospholipases A - antagonists &amp; inhibitors</subject><subject>Phospholipases A - metabolism</subject><subject>Phospholipases A2</subject><subject>Phosphoproteins - metabolism</subject><subject>Piroxicam</subject><subject>Piroxicam - pharmacology</subject><subject>Prostaglandin endoperoxide synthase</subject><subject>Prostaglandin-Endoperoxide Synthases - metabolism</subject><subject>Prostaglandins - metabolism</subject><subject>Proteins</subject><subject>Signal Transduction - drug effects</subject><subject>Tight junctions</subject><subject>Tight Junctions - drug effects</subject><subject>Tight Junctions - metabolism</subject><subject>Time Factors</subject><subject>Western blotting</subject><subject>Zonula Occludens-1 Protein</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU-LFDEQxYMo7uzqB_AiQVlvWVNJp5Pemyz-GVjxouAtpDOJm6U7mU16hPn21jgDC4KnFFW_evXII-QV8CvgXL9vAHxQDEs2CGOYeEJWoLRkA-9-PiUrrkXHjO7gjJy3ds85NzB0z8kZaKml0t2KPHwNU1qWlKlr1GUatmm5w5ab6DbUObgx4XxPQ75z2Yd6RdfXdJ1_h7akX25JJdMSaVoanYNHJLX50HD-7whlvfOFCTqXXCa3D7W9IM-im1p4eXovyI9PH7_ffGG33z6vbz7cMt8ZWJg2o-E9moxxiHrYSDmGTSf63geIzoAeAUS_0Xr0chBRG4cLIPWoRqW4CPKCvDvqbmt52KFfO6fmwzS5HMquWYG_o5Q2CL79B7wvu5rRm8VzCtW1AKTe_JcSyEmlJEJwhHwtrdUQ7bam2dW9BW4PkdljZPZQHiKzAnden4R34xw2jxunjBC4PAGueTfFikGk9sgZ0xvoBvkHbC6dZA</recordid><startdate>20070701</startdate><enddate>20070701</enddate><creator>MAHER, Sam</creator><creator>FEIGHERY, Linda</creator><creator>BRAYDEN, David J</creator><creator>MCCLEAN, Siobhan</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20070701</creationdate><title>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</title><author>MAHER, Sam ; FEIGHERY, Linda ; BRAYDEN, David J ; MCCLEAN, Siobhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-78b806357ff9f79d33bed4266ce1fa817b1126d77bc392f78a8b8137b5b5502e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Actin</topic><topic>Actins - metabolism</topic><topic>Antimicrobial peptides</topic><topic>Aristolochic acid</topic><topic>Aristolochic Acids - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Caco-2 Cells</topic><topic>Cadherins - metabolism</topic><topic>Cell Survival - drug effects</topic><topic>Cellular biology</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Cytotoxicity</topic><topic>Dextrans - chemistry</topic><topic>Dextrans - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>E-cadherin</topic><topic>Electric Impedance</topic><topic>Electrical resistivity</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fluorescein-5-isothiocyanate - analogs &amp; derivatives</topic><topic>Fluorescein-5-isothiocyanate - chemistry</topic><topic>Fluorescein-5-isothiocyanate - metabolism</topic><topic>Fluorescent indicators</topic><topic>Gene expression</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Immunofluorescence</topic><topic>Indomethacin</topic><topic>Indomethacin - pharmacology</topic><topic>Intestinal Absorption - drug effects</topic><topic>Intestinal Mucosa - drug effects</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Mannitol</topic><topic>Medical sciences</topic><topic>Melitten - pharmacology</topic><topic>Membrane Proteins - metabolism</topic><topic>Molecular Weight</topic><topic>Peptides</topic><topic>Permeability</topic><topic>Permeability - drug effects</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phospholipase A2</topic><topic>Phospholipases A - antagonists &amp; inhibitors</topic><topic>Phospholipases A - metabolism</topic><topic>Phospholipases A2</topic><topic>Phosphoproteins - metabolism</topic><topic>Piroxicam</topic><topic>Piroxicam - pharmacology</topic><topic>Prostaglandin endoperoxide synthase</topic><topic>Prostaglandin-Endoperoxide Synthases - metabolism</topic><topic>Prostaglandins - metabolism</topic><topic>Proteins</topic><topic>Signal Transduction - drug effects</topic><topic>Tight junctions</topic><topic>Tight Junctions - drug effects</topic><topic>Tight Junctions - metabolism</topic><topic>Time Factors</topic><topic>Western blotting</topic><topic>Zonula Occludens-1 Protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAHER, Sam</creatorcontrib><creatorcontrib>FEIGHERY, Linda</creatorcontrib><creatorcontrib>BRAYDEN, David J</creatorcontrib><creatorcontrib>MCCLEAN, Siobhan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAHER, Sam</au><au>FEIGHERY, Linda</au><au>BRAYDEN, David J</au><au>MCCLEAN, Siobhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers</atitle><jtitle>Pharmaceutical research</jtitle><addtitle>Pharm Res</addtitle><date>2007-07-01</date><risdate>2007</risdate><volume>24</volume><issue>7</issue><spage>1336</spage><epage>1345</epage><pages>1336-1345</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>Melittin is an amphipathic antimicrobial peptide which has been shown to enhance the permeability of mannitol and reduce transepithelial electrical resistance (TER) across Caco-2 monolayers. The aim of this work was to further examine the potential of melittin as a paracellular permeability enhancer and to investigate the mechanism of interaction with tight junction proteins in Caco-2. The permeability of a range of fluorescent markers of differing molecular weights across monolayers was examined and immunofluorescence and western blotting analysis of tight junction proteins were also carried out. The mechanism of TER reduction was also examined using cell signalling inhibitors. Apical but not basolateral addition of melittin increased the permeability of a range FITC-dextrans (4-70 kDa) across monolayers. Melittin effects were reversible and no cytotoxicity was evident in polarized Caco-2 epithelia at the concentrations used. Altered expression of ZO-1, E-cadherin and F-actin was also detected. The phospholipase A2 inhibitors, aristolochic acid and indomethacin and the cyclooxygenase inhibitor, piroxicam, partially attenuated melittin-induced TER reduction, suggesting that part of the mechanism by which melittin opens tight junctions involves prostaglandin signalling. Apically-added melittin opens tight junctions, causing dramatic TER reductions with significant increases in flux of dextrans. These effects appear mediated in part via PLA2 and involve alterations in specific tight junction proteins.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>17373574</pmid><doi>10.1007/s11095-007-9288-2</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 2007-07, Vol.24 (7), p.1336-1345
issn 0724-8741
1573-904X
language eng
recordid cdi_proquest_miscellaneous_20725578
source MEDLINE; SpringerLink Journals
subjects Actin
Actins - metabolism
Antimicrobial peptides
Aristolochic acid
Aristolochic Acids - pharmacology
Biological and medical sciences
Caco-2 Cells
Cadherins - metabolism
Cell Survival - drug effects
Cellular biology
Cyclooxygenase Inhibitors - pharmacology
Cytotoxicity
Dextrans - chemistry
Dextrans - metabolism
Dose-Response Relationship, Drug
E-cadherin
Electric Impedance
Electrical resistivity
Enzyme Inhibitors - pharmacology
Fluorescein-5-isothiocyanate - analogs & derivatives
Fluorescein-5-isothiocyanate - chemistry
Fluorescein-5-isothiocyanate - metabolism
Fluorescent indicators
Gene expression
General pharmacology
Humans
Immunofluorescence
Indomethacin
Indomethacin - pharmacology
Intestinal Absorption - drug effects
Intestinal Mucosa - drug effects
Intestinal Mucosa - metabolism
Mannitol
Medical sciences
Melitten - pharmacology
Membrane Proteins - metabolism
Molecular Weight
Peptides
Permeability
Permeability - drug effects
Pharmaceutical technology. Pharmaceutical industry
Pharmacology
Pharmacology. Drug treatments
Phospholipase A2
Phospholipases A - antagonists & inhibitors
Phospholipases A - metabolism
Phospholipases A2
Phosphoproteins - metabolism
Piroxicam
Piroxicam - pharmacology
Prostaglandin endoperoxide synthase
Prostaglandin-Endoperoxide Synthases - metabolism
Prostaglandins - metabolism
Proteins
Signal Transduction - drug effects
Tight junctions
Tight Junctions - drug effects
Tight Junctions - metabolism
Time Factors
Western blotting
Zonula Occludens-1 Protein
title Melittin as an epithelial permeability enhancer. I: Investigation of its mechanism of action in caco-2 monolayers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A56%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melittin%20as%20an%20epithelial%20permeability%20enhancer.%20I:%20Investigation%20of%20its%20mechanism%20of%20action%20in%20caco-2%20monolayers&rft.jtitle=Pharmaceutical%20research&rft.au=MAHER,%20Sam&rft.date=2007-07-01&rft.volume=24&rft.issue=7&rft.spage=1336&rft.epage=1345&rft.pages=1336-1345&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1007/s11095-007-9288-2&rft_dat=%3Cproquest_cross%3E20725578%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222663553&rft_id=info:pmid/17373574&rfr_iscdi=true